Dr. Berman Replies

View This PDF

NB: This article is only available as a PDF.

Letter to the Editor

Sir: We thank Drs. Rakofsky and Ghaemi for their inquiry on the recent study published by my colleagues and me. This article reports the first of 2 studies (see also Marcus et al.) in which we present the efficacy and safety of aripiprazole as adjunctive treatment to standard antidepressant therapy (ADT) in patients with major depressive disorder who have had an inadequate response to ADTs. This study showed that adjunctive aripiprazole, compared with adjunctive placebo, significantly improved depressive symptoms as measured by the change in the Montgomery-Asberg Depression Rating Scale total score from baseline, the primary outcome measure.

J Clin Psychiatry 2008;69(6):1021-1022